Literature DB >> 15448688

Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation.

Alberto Lleó1, Oksana Berezovska, Lauren Herl, Susan Raju, Amy Deng, Brian J Bacskai, Matthew P Frosch, Michael Irizarry, Bradley T Hyman.   

Abstract

Recent reports suggest that some commonly used nonsteroidal anti-inflammatory drugs (NSAIDs) unexpectedly shift the cleavage products of amyloid precursor protein (APP) to shorter, less fibrillogenic forms, although the underlying mechanism remains unknown. We now demonstrate, using a fluorescence resonance energy transfer method, that Abeta(42)-lowering NSAIDs specifically affect the proximity between APP and presenilin 1 and alter presenilin 1 conformation both in vitro and in vivo, suggesting a novel allosteric mechanism of action.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15448688     DOI: 10.1038/nm1112

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  72 in total

1.  Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.

Authors:  Hong I Wan; J Steve Jacobsen; J Lynn Rutkowski; Giora Z Feuerstein
Journal:  Clin Transl Sci       Date:  2009-06       Impact factor: 4.689

2.  Interrelationship between Changes in the Amyloid β 42/40 Ratio and Presenilin 1 Conformation.

Authors:  Katarzyna Marta Zoltowska; Masato Maesako; Oksana Berezovska
Journal:  Mol Med       Date:  2016-07-05       Impact factor: 6.354

3.  Phenylpiperidine-type γ-secretase modulators target the transmembrane domain 1 of presenilin 1.

Authors:  Yu Ohki; Takuya Higo; Kengo Uemura; Naoaki Shimada; Satoko Osawa; Oksana Berezovska; Satoshi Yokoshima; Tohru Fukuyama; Taisuke Tomita; Takeshi Iwatsubo
Journal:  EMBO J       Date:  2011-10-14       Impact factor: 11.598

4.  An alternative interpretation of the amyloid Abeta hypothesis with regard to the pathogenesis of Alzheimer's disease.

Authors:  Vincent T Marchesi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-20       Impact factor: 11.205

Review 5.  At the frontline of Alzheimer's disease treatment: gamma-secretase inhibitor/modulator mechanism.

Authors:  Taisuke Tomita
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-24       Impact factor: 3.000

6.  Changing the course of Alzheimer's disease: anti-amyloid disease-modifying treatments on the horizon.

Authors:  Daniel D Christensen
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

Review 7.  The two faces of protein misfolding: gain- and loss-of-function in neurodegenerative diseases.

Authors:  Konstanze F Winklhofer; Jörg Tatzelt; Christian Haass
Journal:  EMBO J       Date:  2008-01-23       Impact factor: 11.598

8.  Neuronal cyclooxygenase-2 activity and prostaglandins PGE2, PGD2, and PGF2 alpha exacerbate hypoxic neuronal injury in neuron-enriched primary culture.

Authors:  Wenjin Li; Shasha Wu; Robert W Hickey; Marie E Rose; Jun Chen; Steven H Graham
Journal:  Neurochem Res       Date:  2007-08-31       Impact factor: 3.996

9.  CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.

Authors:  B P Imbimbo; B Hutter-Paier; G Villetti; F Facchinetti; V Cenacchi; R Volta; A Lanzillotta; M Pizzi; M Windisch
Journal:  Br J Pharmacol       Date:  2009-03       Impact factor: 8.739

10.  Inhibition of Alzheimer's amyloid toxicity with a tricyclic pyrone molecule in vitro and in vivo.

Authors:  Hyun-Seok Hong; Sandeep Rana; Lydia Barrigan; Aibin Shi; Yi Zhang; Feimeng Zhou; Lee-Way Jin; Duy H Hua
Journal:  J Neurochem       Date:  2009-02       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.